Sep 25, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
Sep 24, 2025 • Benzinga
NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Soleno Therapeutics, Inc. - SLNO - Soleno Therapeutics ( NASDAQ:SLNO )
NEW YORK, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ( "Soleno" or the "Company" ) SLNO. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sep 24, 2025 • Benzinga
NEUTRAL
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Acadia Pharmaceuticals Inc. ACAD released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ( ACP-101 ) in patients with hyperphagia in Prader-Willi syndrome ( PWS ) .
Sep 18, 2025 • Benzinga
NEUTRAL
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm - Soleno Therapeutics ( NASDAQ:SLNO )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno ( SLNO ) To Contact Him Directly To Discuss Their Options Click here to participate in the action. NEW YORK, Sept. 18, 2025 ( GLOBE NEWSWIRE ) --
Sep 18, 2025 • Benzinga
NEUTRAL
Soleno Therapeutics ( SLNO ) Drops Amid Critical Scorpion Report -- Hagens Berman - Soleno Therapeutics ( NASDAQ:SLNO )
SAN FRANCISCO, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. SLNO experienced a significant drop following the release of a highly critical report by Scorpion Capital. Hagens Berman, a national shareholders rights firm, has opened an ...
Sep 11, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Soleno Therapeutics ( SLNO ) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Soleno Therapeutics (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the ...